NCT03366441 is a NA clinical trial of Telephone call in Blood Donor, sponsored by Guangzhou Blood Center.

Who is sponsoring NCT03366441?

NCT03366441 is sponsored by Guangzhou Blood Center.

What drugs are being tested in NCT03366441?

Interventions in NCT03366441: Telephone call, SMS.

What condition does NCT03366441 study?

NCT03366441 studies Blood Donor.

Is NCT03366441 still recruiting?

NCT03366441 is currently completed. Last updated 14 November 2018.

Last reviewed 2018-11-14 · How we verify

NCT03366441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reactivation of Inactive Blood Donors

Completed NA Last updated 14 November 2018

What this trial tests

NA trial testing Telephone call in Blood Donor in 11,880 participants. Completed in 5 December 2017.

Timeline

20 October 2016

Primary endpoint
10 November 2017

5 December 2017

Quick facts

Lead sponsor	Guangzhou Blood Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	11,880
Start date	20 October 2016
Primary completion	10 November 2017
Estimated completion	5 December 2017
Sites	1 location across China

Drugs / interventions tested

Telephone call
SMS

Conditions studied

Blood Donor — all drugs for Blood Donor →

Sponsor

Guangzhou Blood Center — full company profile →

Who can join

Adults 18 to 50, any sex, with Blood Donor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Blood donor retention is a critical strategy to ensure the safety and sufficiency of clinical blood supply. An effective strategy can prevent donors from lapsing and eventually becoming inactive.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effective methods for reactivating inactive blood donors: a stratified randomised controlled study.
Ou-Yang J, Bei CH, Liang HQ, He B, et al · · 2020 · cited 10× · PMID 32276613 · DOI 10.1186/s12889-020-08594-9

Verify or expand the search:

Other trials of Telephone call

Trials testing the same drug.

NCT04262908 — Socio-professional Categories and Return to Work After Hip or Knee Replacement Surgery · unknown
NCT03645083 — Patient Adherence to Acupuncture Treatment · NA · completed
NCT04315207 — Breaking Potentially Bad News in Lung Cancer Workup: Telephone Versus In-person Breaking of Final Diagnosis · NA · completed

Other Guangzhou Blood Center trials

Trials by the same sponsor.

NCT05213130 — Blood Donation and Subjective Well-being · NA · completed
NCT05319951 — Effect of Different Liquids Intake in Vasovagal Reaction After Whole Blood Donation · NA · completed
NCT04484896 — Message Framing on Recruiting Rh-D Negative Blood Donors · NA · unknown
NCT04431180 — Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial# · NA · unknown
NCT04410458 — Recruit Blood Donors Via SMS During Epidemic of COVID-19 （Repeat Trial） · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03366441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Blood Center
Last refreshed: 14 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03366441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing